Post-ERCP Pancreatitis Prevention in 2026: Rectal NSAIDs, Pancreatic Stents, and Practical Risk Reduction

Clinical Bottom Line

Prevention step	2026 practical answer
Rectal NSAIDs	Give rectal indomethacin 100 mg (or diclofenac 100 mg per ESGE) to most adults undergoing ERCP unless there is a clear contraindication (recent peptic ulcer, significant renal insufficiency). ASGE 2023 [1]: unselected and high-risk. ESGE 2020 [3]: immediately before ERCP.
Cannulation strategy	Wire-guided cannulation over contrast-guided cannulation (ASGE, moderate-quality).
High-risk pancreatic duct access	Do not rely on NSAIDs alone when the PD has been repeatedly or deeply accessed. Prophylactic pancreatic stenting still matters. SVI [7] 2024: indomethacin alone 14.9% vs combination 11.3% in high-risk patients. Failed noninferiority.
Hydration	Aggressive lactated Ringer's remains reasonable in selected patients if heart failure, renal insufficiency, or advanced liver disease are not limiting.
Best mental model	PEP prevention is a bundled strategy, not a single suppository. Stone extraction lives on the ERCP stones post.

What do the societies say?

Do not use Levenick [6] 2016 to skip rectal NSAIDs in high-risk ERCP. That trial was consecutive, mostly average-risk, and stopped for futility. Elmunzer 2012 [4] still stands. Do not treat SVI 2024 [7] as permission to skip the stent in high-risk patients who have had repeated PD access.

What is the PEP prevention stack?

ASGE 2023 (Buxbaum summary, PMID 36517310) remains the US procedural frame: rectal NSAIDs for unselected and high-risk patients, wire-guided cannulation, prophylactic pancreatic stents when the PD is repeatedly or deeply accessed, and selective aggressive hydration. ESGE 2020 (Dumonceau, PMID 31863440) recommends 100 mg rectal diclofenac or indomethacin immediately before ERCP in all patients without NSAID contraindications, and prophylactic pancreatic stenting in selected high-risk patients (inadvertent PD wire or opacification, double-guidewire cannulation).

Elmunzer NEJM 2012 is still the high-risk NSAID anchor: PEP 9.2% with rectal indomethacin vs 16.9% placebo in high-risk ERCP, mostly suspected sphincter of Oddi. Luo [5] 2016 (unselected Chinese multicenter, n=2600): universal pre-procedural indomethacin 4% vs risk-stratified post-procedural 8%. That is the best argument for giving the suppository before you start, not after you decide the case "looked easy."

Levenick 2016 (consecutive patients, ~70% average-risk, n=449, stopped for futility): PEP 7.2% indomethacin vs 4.9% placebo, not significant. Do not use Levenick to skip NSAIDs in high-risk patients. Elmunzer 2012 still stands. ASGE still recommends NSAIDs in unselected ERCP. Levenick is the honest average-risk caveat, not a reason to empty the NSAID drawer.

Those three NSAID trials are not interchangeable populations. Elmunzer 2012 was high-risk and SOD-heavy. Luo was mostly stone extraction in unselected Chinese adults. Levenick was consecutive Dartmouth ERCPs, mostly average-risk. Quote the trial that matches the patient in front of you. Do not use an average-risk futility stop to override a high-risk RCT, and do not pretend Luo proved that every 85-year-old with a 4 mm stone needs the same intensity as a young woman with suspected SOD.

Buxbaum 2014 is the hydration protocol ASGE still cites: lactated Ringer's at 3 mL/kg/h during the procedure, 20 mL/kg bolus after, then 3 mL/kg/h for 8 hours. It was a small RCT. Later hydration trials in hospitalized patients pointed the same way. It is not a license to volume-load outpatients with heart failure. Choudhary's pancreatic-stent meta remains the device-level backup for placing a stent when the PD has been instrumented, before SVI made the NSAID-alone shortcut look tempting.

Can I skip the pancreatic stent if I gave indomethacin?

Elmunzer Lancet 2024 (SVI, 20 North American centers, n=1950 high-risk): indomethacin alone 14.9% vs indomethacin plus prophylactic pancreatic stent 11.3%. Risk difference 3.6% (95% CI 0.6-6.6). Failed the 5% noninferiority margin. Post-hoc ITT: indomethacin alone was inferior (P=0.011). In a high-risk patient who meets the technical threshold for prophylactic pancreatic stenting, NSAID monotherapy is not the evidence-based shortcut.

A 2024 high-risk rescue-cannulation cohort (Choi, n=607) found no additional benefit from indomethacin when patients were already receiving prophylactic pancreatic stents. That does not overturn SVI. It highlights a narrower unresolved question once reliable stent-based drainage is in. Until stronger data resolve that point, follow the bundled ASGE strategy rather than simplifying it.

What do I do tonight?

1. If before cannulation: Screen for NSAID contraindications, identify baseline PEP risk, give the suppository, and make the stent plan explicit before starting.
2. If during cannulation: Wire-guided technique. Avoid repeated contrast injection or forceful PD manipulation.
3. If if the PD is repeatedly or deeply accessed: Place a prophylactic pancreatic stent. Do not assume rectal indomethacin alone is enough (SVI).
4. If periprocedural hydration: When appropriate, lactated Ringer's with a 20 mL/kg bolus and 3 mL/kg/h for 8 hours. Easier for inpatients. Unsafe in heart failure, renal insufficiency, or advanced liver disease.
5. If after the case: Track spontaneous stent migration or remove the stent in 2-4 weeks if needed. Do not miss early pain that reflects evolving PEP.

This page is the prevention bundle. Balloon vs EPLBD vs lithotripsy vs cholangioscopy is the stone-extraction algorithm. Do not duplicate that here. Tokyo drainage timing for cholangitis lives there too.

Pitfalls

Pitfall	Better move
Treating post-procedure rectal indomethacin as the entire strategy	Luo favors giving it before you start. Technique still matters.
Using Levenick to skip NSAIDs in high-risk ERCP	Levenick is consecutive/average-risk and stopped for futility. Elmunzer 2012 and ASGE still want NSAIDs in high-risk patients.
Skipping the pancreatic stent because NSAIDs were given	SVI 2024: indomethacin alone failed noninferiority vs indomethacin plus stent.
Aggressive hydration in heart failure or CKD	Selective, not indiscriminate.
Citing EPISOD as a PEP-prevention trial	EPISOD is SOD type III, not a prevention bundle.

Selected references

1. Buxbaum JL, et al. ASGE guideline on PEP prevention: summary. Gastrointest Endosc. 2023.
2. Buxbaum JL, et al. ASGE PEP prevention: methodology and evidence. Gastrointest Endosc. 2023.
3. Dumonceau JM, et al. ESGE: ERCP-related adverse events. Endoscopy. 2020.
4. Elmunzer BJ, et al. Rectal indomethacin to prevent PEP. N Engl J Med. 2012.
5. Luo H, et al. Routine pre-procedural vs selective post-procedural indomethacin. Lancet. 2016.
6. Levenick JM, et al. Rectal indomethacin in consecutive ERCP patients. Gastroenterology. 2016.
7. Elmunzer BJ, et al. SVI: indomethacin with or without pancreatic stent. Lancet. 2024.
8. Indomethacin does not reduce PEP in high-risk patients already receiving pancreatic stents. Dig Dis Sci. 2024.
9. Buxbaum J, et al. Aggressive hydration with lactated Ringer's solution. Clin Gastroenterol Hepatol. 2014.
10. Tse F, Yuan Y, Moayyedi P, Leontiadis GI. Guidewire-assisted cannulation. Cochrane Database Syst Rev. 2012.
11. Choudhary A, et al. Pancreatic stents for prophylaxis against PEP. Gastrointest Endosc. 2011.
12. Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis. Endoscopy. 2010.